HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of Fc γR-binding functionality

ConclusionIn this manuscript, we describe the development of HERA-GITRL, a true GITR agonist with a clearly defined mechanism of action. By clustering six receptor chains in a spatially well-defined manner, HERA-GITRL induces potent agonistic activity without being dependent on additional Fc γR-mediated crosslinking.

http://link.springer.com/10.1186/s40425-019-0671-4

Source: Journal for Immunotherapy of Cancer - July 18, 2019 Category: Cancer & Oncology Source Type: research

More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Immunotherapy